Published July 7, 2021
| Version v1
Journal article
Open
Implementing Outcomes‑Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
Creators
- 1. University of Edinburgh, Scotland
- 2. Andalusian School of Public Health
- 3. National Institute for Health and Care Excellence, England
- 4. Zorginstituut Nederland
- 5. Bocconi University, Italy
- 6. National Centre for Pharmacoeconomics, Ireland
- 7. Catholic University of the Sacred Heart, Italy
- 8. National Institute for Health and Disability Insurance, Belgium
- 9. Agency for HTA and Tariff System, Poland
- 10. Sofia University, Bulgaria
- 11. Vilnius University, Lithuania
Description
Comparison of the constructs of Outcomes-Based Managed Entry Agreements (OBMEA) for nusinersen and tisagenlecleucel in countries in Europe, Canada and Australia leading to recommendations about OBMEA implementation and the need for collaboration across countries.
Files
Facey 2021 OBMEA case studies published.pdf
Files
(919.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:f4361b9470b4c392087ddb4171437fcb
|
919.2 kB | Preview Download |